

8 March 2017

Omni Innovation US Update

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

US Distribution

Following a broad search Omni Innovation has shortlisted several suitable US companies for the manufacture of its patented pre-meal drink for people with diabetes for distribution in the US. Shortlisted manufacturers were identified based on manufacturing capabilities, distribution and logistics management nationally across the US and international export readiness and experience.

Distribution in the US of the GlucoSmooth™ technology is expected to be a combination of direct sales channels as well as traditional pharmacy/healthcare retail outlets. The pre-meal drink will be sold in the US under the brand name GlucoSmooth™ and the appointment of the preferred manufacturer is expected in the next two weeks and subsequently the first production run is expected to commence within 4-6 weeks of this appointment.

Marketing assets are currently under development in the US based on learnings and experience from the launch in the Australian market.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

About Omni Innovation

Omni Innovation is a private Melbourne based medical and functional food R&D company. Omni Innovation have, and continue to develop clinically validated and evidence-based dietary interventions in the areas of type-2 diabetes, pre-diabetes, medical weight management to improve health and quality of life.

In 2016 a license to Symbion Ltd (EBOS Ltd) was granted for the distribution of Faulding® GlucoControl™ for the dietary management of type 2 diabetes and pre-diabetes for release to the Australian market under their fully owned Faulding® brand.

For more information, please visit www.omniinnovation.com.au

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au